Vectus Biosystems (ASX:VBS) FCF Margin % : -86,200.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vectus Biosystems's Free Cash Flow for the six months ended in Dec. 2023 was A$-0.86 Mil. Vectus Biosystems's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Vectus Biosystems's FCF Margin % for the quarter that ended in Dec. 2023 was -86,200.00%.

As of today, Vectus Biosystems's current FCF Yield % is -27.34%.

The historical rank and industry rank for Vectus Biosystems's FCF Margin % or its related term are showing as below:

ASX:VBS' s FCF Margin % Range Over the Past 10 Years
Min: -138200 Med: -65533.33 Max: -65533.33
Current: -138200

During the past 8 years, the highest FCF Margin % of Vectus Biosystems was -65533.33%. The lowest was -138200.00%. And the median was -65533.33%.

ASX:VBS's FCF Margin % is ranked worse than
98.15% of 1028 companies
in the Biotechnology industry
Industry Median: -136.71 vs ASX:VBS: -138200.00

Vectus Biosystems FCF Margin % Historical Data

The historical data trend for Vectus Biosystems's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems FCF Margin % Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial											-	-	-20,555.56	-	-86,200.00

Competitive Comparison of Vectus Biosystems's FCF Margin %

For the Biotechnology subindustry, Vectus Biosystems's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vectus Biosystems's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's FCF Margin % falls into.

Vectus Biosystems FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vectus Biosystems's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-2.37	/	0
	=	%

Vectus Biosystems's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.862	/	0.001
	=	-86,200.00 %

Vectus Biosystems FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems Headlines

No Headlines